Mercury Acquisitions Corp. Will Combine With Franchise Cannabis Corp.
Mercury Acquisitions Corp. Will Combine With Franchise Cannabis Corp.
The resulting issuer plant to continue to ran Franchise’s business in the medical cannabis and pharmaceutical industries and be listed on the TSXV. Mercury Acquisitions Corp. (TSXV:MERC) announced Thursday its subsidiary 2868303 Ontario Inc., also known as Mercury Subco will amalgamate with Franchise Cannabis Corp. to finalize the company’s qualifying transaction in relation to the policies of the TSX Venture Exchange.
水星收购公司(TSXV：MERC)周四宣布其子公司2868303安大略省公司，也被称为水星分部 将与特许经营大麻公司合并，以敲定该公司的资格交易关于多伦多证券交易所创业板的政策。
Under the amalgamation agreements, the combined corporation (Amalco) will be a wholly-owned subsidiary of Mercury, which will be renamed to Franchise Global Health Inc. upon the completion of the combination. At the same time, the corporate name of Amalco will be Franchise Cannabis Corp.
根据合并协议，合并后的公司(Amalco)将是水星公司的全资子公司，水星公司将更名为特许经营全球健康公司。在完成合并之后。同时，阿马尔科的公司名称将是特许经营大麻公司。.
The Transaction is subject to the receipt of all necessary regulatory and shareholder approvals, including approval of the TSXV, as well as the satisfaction of conditions to closing as set out in the agreement.
交易须获得所有必要的监管及股东批准，包括多伦多证券交易所的批准，以及是否符合协议所载的成交条件。
The resulting issuer plant to continue to ran Franchise’s business in the medical cannabis and pharmaceutical industries and be listed on the TSXV.
这个由此产生的发行人工厂将继续经营特许经营的医用大麻和制药行业的业务，并在多伦多证券交易所上市。
About Franchise: Franchise is a multi-national operator in the medical cannabis and pharmaceutical industries, with core operations in Germany and with operations, assets, strategic partnerships and investments internationally, including Canada, Denmark, Colombia, St. Vincent and the Grenadines, and Portugal.
关于特许经营：特许经营权是a 医用大麻和制药行业的跨国运营商，核心业务在德国以及与国际业务、资产、战略伙伴关系和投资的合作，包括加拿大、丹麦、哥伦比亚、圣文森特和格林纳丁斯以及葡萄牙.
The company aims to develop a fully integrated, leading European medical cannabis business, with the goal of providing high-quality pharmaceutical-grade medical cannabis to distribution partners and, ultimately, to patients, at competitive prices.
该公司旨在发展完全整合的、领先的欧洲医用大麻业务，目标是向分销伙伴提供高质量的药用大麻，并最终以具有竞争力的价格向患者提供。
What’s more, Franchise has also entered into an agreement to acquire Phatebo GmbH, which is focused on wholesale pharmaceutical distribution through import and export capabilities of a wide range of pharmaceutical and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, ADHD, multiple sclerosis and anti-depressants, among others. Phatebo conducts its business of distributing pharmaceutical products within 18 countries globally, primarily in Europe, but also with sales to Asia, Latin America and North America
更重要的是，特许经营也有达成协议收购Phatebo GmbH，它的重点是药品批发配送通过广泛的医药和医用大麻产品的进出口能力，治疗各种健康适应症，包括与癌症治疗、ADHD、多发性硬化症和抗抑郁药等相关的药物。Phatebo从事医药产品分销业务在全球18个国家内，主要销往欧洲，但也销往亚洲、拉丁美洲和北美
Photo: Courtesy of CRYSTALWEED cannabis on Unsplash
图片：Unspash上的结晶器大麻提供
